France Mycoplasma Testing Market Market Report 2023 to 2030

France Mycoplasma Testing Market Analysis

$ 3999

France Mycoplasma Testing Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Mycoplasma Testing is expanding as a result of growing cell culture contamination and increased investment in research & development. This demand is fueling the development of better mycoplasma testing methods. Some of the key players in the global Mycoplasma Testing Market include Bionique Testing Laboratories LLC, Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd, Charles River Laboratories, Inc., Merck KGaA, Lonza Group Ltd, American Type Culture Collection, Thermo Fisher Scientific Inc., Invivogen, Eurofins Scientific, Norgen Biotek Corp., SGS S.A., and Promocell GmbH.

ID: IN10FRHS076 CATEGORY: Healthcare Services GEOGRAPHY: France AUTHOR: Aneri Parekh

Buy Now

France Mycoplasma Testing Market Executive Summary

France Mycoplasma Testing Market is valued at around $23.1 Bn in 2022 and is projected to reach $58.9 Bn by 2030, exhibiting a CAGR of 12.4% during the forecast period 2023-2030.

Mycoplasmas frequently contaminate the fluids used in bioprocessing and cell culture. It is widely recognized that primary cell cultures have a minimum contamination rate of 1% and continuous cell cultures have a contamination rate of between 15 and 35% due to mycoplasma. Detecting mycoplasma contamination requires specialized testing because it is difficult to see with a microscope which can proliferate the growth of Mycoplasma Testing in the market.

The mycoplasma testing market is expanding as a result of innovative approaches and sizable investments by market players. This reflects the growth of biologics in the world market. Numerous biologic products, such as monoclonal antibodies, viral vaccines, and cytokines, which are employed for medical or therapeutic purposes, are produced using cell lines. Mycoplasma strains have a substantial impact on the physiology, metabolism, and gene expression of cell lines. These are certain factors that drive the growth of the Mycoplasma Testing market.

Pharmaceutical and Biopharmaceutical firms like include Bionique Testing Laboratories LLC, Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd, Charles River Laboratories, Inc., Merck KGaA, Lonza Group Ltd, American Type Culture Collection, Thermo Fisher Scientific Inc., Invivogen, Eurofins Scientific, Norgen Biotek Corp., SGS S.A., and Promocell GmbH, are some of the major players in the Mycoplasma Testing Market.

The adoption of innovative technologies for drug development processes is due to more market research conducted by pharmaceutical corporations. Mycoplasma testing market expansion has been accelerated by large investments made by leading companies. The market's research initiatives in the biotechnology and pharmaceutical industries are both heavily subsidized by a number of government agencies. Therefore, increased government financing for R&D initiatives is driving the Mycoplasma Testing market.

An important factor driving the growth of the mycoplasma diagnostics market is the rise in the number of elderly people suffering from respiratory conditions. The World Health Organisation (WHO) reported that lung cancer and respiratory tract infections affected 34.3% of the elderly population. Effective mycoplasma diagnosis is necessary to treat chronic respiratory diseases, which will eventually drive the global market for mycoplasma testing.

Market Dynamics

Drivers of France Mycoplasma Testing Market:

Growing Concerns over Cell Culture Contamination: Cell culture contamination is the most common issue in cell culture labs. Mycoplasma Testing is used for contamination detection, boosting the growth of the market.

Increasing Research & Development Investment: Rising costs of research and increased investment in research & development is anticipated to boost the market for Mycoplasma Testing.

Technological Advancements: Mycoplasma Testing market share is growing as a result of technological developments including the creation of quicker and more precise mycoplasma testing methods and equipment like PCR and DNA staining.

Developments in Mycoplasma Testing Market:

In 2022, BioMérieux and NecstGen partnered to develop C-Therapies Cellular and Genetic Testing that would enable the production of safe and effective advanced therapies through rapid testing technologies.

In 2022, Bioprocess Intl released guidelines for mycoplasma testing, providing companies with actionable and fast data for batch release and raw material testing, whose contamination has proven to be a risk for the manufacture of cell-based biologics.

In 2022, Abbott received United States Food and Drug Administration approval for its Alinity m STI Assay. The test simultaneously detects and differentiates four common sexually transmitted infections (STIs), including Mycoplasma genitalium (MG).

In 2022, Performer Availability Screening Service, Inc. (PASS) entered into a partnership with Spankchain to launch a screening and treatment initiative for Mycoplasma genitalium infection in the Las Vegas performer community at no cost for up to 1000 performers.

Key players

Merck KGaA Thermo Fisher Scientific, Inc. Charles River Laboratories International, Inc. Lonza Group Ltd. Eurofins Scientific SE PromoCell GmbH Sartorius AG Biological Industries France SARL ATCC (American Type Culture Collection) GenBio Laboratories, Inc.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For France Mycoplasma Testing Market

By Product:

Kits and Reagents
Instruments
Services
Others

By Technique:

PCR
ELISA
Direct Assays
Indirect Assays
DNA Staining
Microbial Culture Techniques
Enzymatic Methos

By Application:

Cell Line Testing
Virus Testing
End-of-Production Cell Testing
Others

By Distribution Channel:

Retail
Direct Tenders

By End-user:

Hospitals and Surgical Centers
Clinics
Community Healthcare
Academic Research Institutes
Cell Banks
Contract Research Organizations
Pharmaceuticals and Biotechnology Companies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.